TFX

Teleflex Incorporated

Healthcare
128.56 +3.32 +2.65% Market Closed
2026-06-03 • USD

Key Metrics

Market Cap 5.69B
EV —
Shares Out 44.27M
Revenue (ttm) 2.13B
Net Income -1.01B
Beta —
P/E -33.10
Forward P/E —
EPS (ttm) $-22.50
P/S —
P/B 1.84
P/FCF —
P/C —
EV/Sales —
EV/EBITDA —
ROA -14.87%
ROE -27.54%
ROIC —
Gross Margin 55.14%
Oper. Margin 2.95%
Profit Margin -47.43%
Debt/Eq 0.90
LT Debt/Eq 44.91%
Quick Ratio —
Current Ratio 2.55
Book/sh 69.69
Cash/sh 6.99
Div Yield 1.06%
Div TTM $1.36
Payout Ratio —
SMA20 -1.16%
SMA50 2.08%
SMA200 7.12%
Volume 660,105
Avg Volume 907.17K
Rel Volume —
Perf Week -0.85%
Perf Month 7.23%
Perf Quarter 7.87%
Perf Half Y 8.16%
Perf YTD 5.34%
Perf Year 4.73%
Perf 3Y -45.63%
Perf 5Y -67.47%

Factor Lens

Seasonal Performance

Dividends

Per-share amounts adjusted for stock splits.

Last Dividend $0.3400
TTM Yield 1.06%
TTM Amount $1.36
Payout Ratio —
3-Yr Growth (CAGR) 0.00%
5-Yr Growth (CAGR) 0.00%

Last 12 Payouts

Period Ex-Date Amount / Share
Q1 2026 ~2026-03-31 $0.3400
Q4 2025 ~2025-12-28 $0.3400
Q3 2025 ~2025-09-28 $0.3400
Q2 2025 ~2025-06-29 $0.3400
Q1 2025 ~2025-03-30 $0.3400
Q4 2024 ~2024-12-29 $0.3400
Q3 2024 ~2024-09-29 $0.3400
Q2 2024 ~2024-06-30 $0.3400
Q1 2024 ~2024-03-31 $0.3400
Q4 2023 ~2023-12-31 $0.3400
Q3 2023 ~2023-10-01 $0.3400
Q2 2023 ~2023-07-02 $0.3400

Financial Trends

Revenue & Net Income

Earnings Per Share

Margins

Cash Flow

Company Overview

Teleflex Incorporated is a global provider of medical technology products that enhance clinical benefits, improve patient and provider safety and reduce total procedural costs. The Company primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. Products are marketed and sold worldwide through a combination of direct sales force and distributors. The Company's product portfolio comprises three main categories: Vascular and Emergency Medicine (including Arrow branded catheters, catheter navigation systems, and intraosseous access systems); Interventional (coronary and peripheral intervention devices including catheters, stents, and balloon products); and Surgical (single-use and reusable devices for various surgical procedures including ligating clips, fascial closure systems, and surgical instruments). Major manufacturing operations are located in the Czech Republic, Malaysia, Mexico and the United States. The Company operates through three reportable geographic segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). In July 2025, Teleflex acquired substantially all of BIOTRONIK's Vascular Intervention business, expanding its coronary and peripheral device offerings. In December 2025, the Company announced agreements to sell its Acute Care, Interventional Urology and OEM businesses for approximately $2.0 billion in combined proceeds, with closing expected in the second half of 2026.

Name
Teleflex Incorporated
Industry
Medical Devices
CEO
Stuart A. Randle · Interim President and Chief Executive Officer
Employees
10,900 as of 2025-12-31
IPO Date
2011-12-01
Phone
(610) 225-6800
Address
550 East Swedesford Road, Suite 400, Wayne, PA 19087
Website
http://www.teleflex.com

Key Executives

Name Title FY Pay
Jaewon Ryu, M.D. Director and Compensation Committee Member —
Andrew A. Krakauer Director and Chair of Compensation Committee —
Gretchen R. Haggerty Director and Audit Committee Member —
Candace H. Duncan Director and Chair of Audit Committee —
Stuart A. Randle Interim President and Chief Executive Officer —

Latest News